CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity ProgramBusiness Wire • 08/09/22
Cybin Inc. Reports First Quarter Financial Results and Recent Business HighlightsBusiness Wire • 08/08/22
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 07/12/22
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive DisorderBusiness Wire • 06/27/22
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business HighlightsBusiness Wire • 06/22/22
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022Business Wire • 06/16/22
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 06/09/22
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training ProgramBusiness Wire • 06/03/22
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic TherapyBusiness Wire • 06/02/22
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 05/31/22
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022Business Wire • 05/11/22